Treatment | Day of treatment or re-infestation | ||||||
---|---|---|---|---|---|---|---|
0 | 7 | 14 | 21 | 28 | 35 | ||
Placebo | Range | 4–22 | 14–31 | 7–33 | 9–36 | 17–36 | 9–26 |
A. mean | 14.1 | 21.1 | 22.3 | 22.0 | 28.4 | 20.3 | |
G. mean2 | 12.6a | 20.2a | 20.1a | 19.9a | 27.4a | 19.1a | |
Sarolaner | Range | 0–0 | 0–0 | 0–2 | 0–2 | 0–9 | 1–20 |
A. mean | 0.0 | 0.0 | 0.5 | 0.4 | 3.6 | 8.0 | |
Efficacy (%) | 100 | 100 | 97.8 | 98.3 | 87.2 | 60.5 | |
G. mean2 | 0.0b | 0.0c | 0.4c | 0.3c | 2.5c | 5.5b | |
Efficacy (%) | 100 | 100 | 98.2 | 98.7 | 91.1 | 70.9 | |
P-value vs.placebo | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | |
Afoxolaner | Range | 0–0 | 0–4 | 0–11 | 3–16 | 9–29 | 10–23 |
A. mean | 0.0 | 1.5 | 4.5 | 9.8 | 17.7 | 18.0 | |
Efficacy (%) | 100 | 92.9 | 79.8 | 55.3 | 37.7 | 11.1 | |
G. mean2 | 0.0b | 0.9b | 3.0b | 8.5b | 16.1b | 17.0a | |
Efficacy (%) | 100 | 95.3 | 84.9 | 57.6 | 41.5 | 10.6 | |
P-value vs. placebo | <0.0001 | <0.0001 | <0.0001 | 0.0025 | 0.0487 | 0.6801 | |
P-value vs. sarolaner | 0.9525 | 0.0247 | 0.0003 | <0.0001 | <0.0001 | 0.0007 |